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ABSTRACT  
   
Despite recent strides for awareness, treatment, and control of hypertension, 
prevalence remains high with estimates suggesting one third of Americans have 
hypertension. The hypotensive effects of potassium and magnesium have been known 
and administered in a clinical setting for nearly a century. The purpose of this study was 
to examine the effectiveness of taking a potassium/magnesium supplement to help reduce 
blood pressure in individuals with mildly-moderately elevated blood pressure. In this 
randomized, controlled crossover trial, potassium and magnesium supplementation was 
explored among healthy adults with mildly elevated blood pressure in Phoenix, Arizona. 
Subjects (n = 12) were randomly assigned to ingest either the treatment chewy bar (217 
mg potassium/day; 70.8 mg magnesium/day) or a placebo chewy bar for four weeks. For 
the subsequent four weeks, subjects ingested the other corresponding chewy bar. Systolic 
(SBP), diastolic (DBP), and average blood pressure values were not significantly 
different between the two groups (p = 0.645, p = 0.464 and p = 0.939, respectively). 
Baseline mean blood pressure was 121.0/75.7 mm Hg. The 12 subjects (8 females, 4 
males) had a mean age of 29.3 years old and a mean BMI of 26.2. After four weeks, the 
treatment group had a slightly higher SBP (118.3 ± 13.3 mm Hg) than the control group 
(116.5 ± 17.8 mm Hg); however, DBP was lower in the treatment group (71.7 ± 12.4 mm 
Hg) than the control group (73.0 ± 10.0 mm Hg). In conclusion, daily supplementation of 
potassium and magnesium (217.2 mg/day and 70.8 mg/day, respectively) did not 
significantly lower blood pressure in adults with mildly-moderately elevated blood 
pressure. 
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CHAPTER 1 
INTRODUCTION 
Problem 
Considered one of the highest and most preventable causes of death, 
hypertension affects one out of three Americans and was responsible for approximately 
one out of every five deaths among U.S. adults in 2005 (1-3). Such a burden on the 
American health care system is evident from an estimate of lifetime risk among middle-
aged and the elderly, for developing hypertension, which is a staggering 90% (4). This 
enormous demand on our health care system urges for more effective and/or 
concomitant methods of treatment for high blood pressure. Despite the fact that the past 
two decades have shown progress in the United States for awareness, treatment and 
control of hypertension, coincidentally the overall prevalence of hypertension has also 
increased (2). This alarming trend highlights not only a national success in campaigns 
to heighten awareness, treatment and control; but iteratively and more importantly, a 
growing urgency for alternative or concomitant approaches to combat overall 
prevalence of hypertension and pre-hypertension.  
Considering the enormity of the burden on the health care system, focusing 
more on preventive measures to decrease prevalence of pre-hypertension and 
hypertension has tremendous potential to improve public health outcomes. Even modest 
reductions (i.e. 1,200 mg/day decrease) in population-wide sodium intake have been 
estimated to annually reduce approximately 32,000-66,000 strokes, 54,000-99,000 heart 
attacks, and 44,000-92,000 overall deaths (5). Additionally, this population-wide 
reduction would decrease annual health care costs an estimated $10-$24 billion (5).   
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Beyond the mainstay of pharmaceuticals for treatment, there is an abundance of 
evidence identifying the relationship between many dietary factors and effects on blood 
pressure (6-8). The most common non-pharmaceutical remedy for hypertension is the 
Dietary Approaches to Stop Hypertension dietary pattern (“DASH diet”). Evidence 
supporting the efficacy of the DASH diet is strong enough that this dietary pattern is a 
recommendation in national guidelines (5,7-11). Compared to a standard American 
diet, one of the notable characteristics of the DASH diet is that the recommended food 
components generally have lower values of sodium and higher values of potassium and 
magnesium. More specifically, The DASH Diet emphasizes intake of fruits, vegetables, 
and low-fat dairy products; includes poultry, fish, nuts, seeds, and whole grains; and 
limits the amount of red meats, sweets, and sugar-sweetened beverages. Basing one’s 
dietary pattern on these foods, the DASH Diet offers rich sources of potassium, 
magnesium, calcium, and dietary fiber; while limiting the intakes of total fat, saturated 
fats, and sodium (8). Contrasting from The DASH Diet, over 60% of people in the 
United States are below the Recommended Dietary Allowance (RDA) for magnesium 
and less than 10% of the citizenry consume at least the Adequate Intake (AI) for 
potassium, according to NHANES (National Health and Nutrition Examination Survey) 
data collected between 2001-2008 (12).   
There is a large range of dosage values of potassium and magnesium used for a 
variety of heterogeneously designed studies. The study that was used to base the dosage 
values of the present study on, conducted by Wu et al, found a reduction of 7.83 mm 
Hg systolic blood pressure (p < 0.01) and 3.67 mm Hg diastolic blood pressure (p < 
0.05) on four weeks of potassium-magnesium supplementation (13). Compared to other 
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supplementation studies demonstrating blood pressure lowering effects of potassium 
and magnesium, these were the lowest dosage values used. For instance, other 
controlled trials demonstrating significant blood pressure reduction from potassium 
supplementation ranged from 1,170 mg/day and even exceeding ten times the amount 
used in the present study, with dosage values of 3,000 and even 4,680 mg/day, with no 
reported adverse health outcomes (14-16). Efficacious dosages of magnesium used in 
other controlled trials range from 368 mg/day to 600 mg/day (18, 19).  Despite Wu and 
colleagues demonstrating efficacy with these relatively low dosage values, these results 
were measured in a hypertensive population.  
Although the antihypertensive effects of potassium and magnesium have been 
documented and used in clinical settings for nearly a century (19, 20), inconsistent 
clinical trial findings and the high degree of correlation between multiple dietary 
factors has unfortunately yielded insurmountable evidence for adopting 
recommendations in non-clinical settings, such as for pre-hypertensive individuals. 
However, it is possible that a functional food (i.e. potassium and magnesium 
supplement) can help lower blood pressure for individuals with mild hypertension and 
ultimately can reduce dependence on pharmaceuticals.  
Proposed Research 
Currently, the primary choice of treatment for hypertension in the U.S. is 
pharmacotherapy (7). With medications as the most prominent treatment option, 
interventions aimed at modifying lifestyle and dietary factors are often ignored. The 
objective of this randomized, placebo-controlled crossover trial was to measure the 
effects of daily potassium and magnesium supplementation (217.2 mg/day and 70.8 
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mg/day, respectively) in adults with mildly-moderately elevated blood pressure over an 
8-week period. Additionally, this study will contribute to the pool of evidence that 
suggests that potassium and magnesium supplementation can potentially reduce or in 
some instances replace pharmacotherapy as a sole method of treating hypertension.  
Rather than focus on greater awareness and compliance to a didactic but proven 
effective dietary model (i.e. DASH diet) (21) for hypertension, this study aimed to 
explore the effectiveness and feasibility of taking a potassium/magnesium supplement 
(i.e. functional food) to help attenuate pre-/hypertension. It was hypothesized that daily 
supplementation of potassium and magnesium (217.2 mg/day and 70.8 mg/day, 
respectively) over a 4-week period will lower blood pressure in comparison to a 
placebo in adults with mildly elevated blood pressure in Phoenix, Arizona.  
Definition of Terms 
Antihypertensive: causes a decrease in blood pressure  
Cardiovascular Disease: one of many diseases of the heart and/or blood vessels 
Diastolic/diastole: referring to the time between heartbeats, in a period of relaxation 
Hypertension: elevated blood pressure, greater than or equal to 140 mm HG systolic 
blood pressure and 90 mm HG diastolic (≥ 140/90 mm Hg) 
Hypotensive: the ability to lower blood pressure 
Kaliuretic: promotes increased urinary excretion of potassium 
Natriuretic/Natriuresis: promotes increased urinary excretion of sodium 
Nephron: microscopic functional unit of the kidney 
Renal: of or relating to the kidney 
Systolic/systole: blood pressure while the heart is contracting 
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Delimitations and Limitations 
Limitations of this study include the number of subjects recruited; only 12 
subjects were recruited because the study was unfunded. Although participants were 
instructed to complete compliance calendars, compliance with protocol is another 
limitation of the study. Recording accurate dietary intake data was another limitation, 
which was related to limited reliability and validity using The Food Processor dietary 
analysis database. Additionally, other potential stressors not accounted for in 
participants’ lives are potential limitations.  
Participation in this study was delimited to adults (>18 and <80 years old) who 
reported no past heart disease, renal insufficiency, liver disease (or other organ 
pathology), pregnancy/lactation, or medication use for hypertension. Additionally, 
participation was delimited to those who had a recorded systolic blood pressure (SBP) 
reading (mean of two readings) of >115 mm Hg and <139 mm Hg; and a diastolic 
blood pressure (DBP) of  >70 and <90 mm Hg. Therefore, results of this study will not 
be generalizable to other individuals or populations.   
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CHAPTER 2 
LITERATURE REVIEW 
Blood Pressure Overview 
Current State of Hypertension 
Although health officials in the United States have made recent strides for 
awareness, treatment, and control of hypertension, the ongoing rise in prevalence of 
hypertension (2) suggests that the conventional education and common remedies for 
hypertension may not be sufficient. The attention placed on hypertension along with 
more opportunities to be screened for high blood pressure have increased diagnosis of 
the condition, however nearly 1/3 of those who are hypertensive are still unaware of 
their condition and over 1/3 of hypertensive patients are not taking treatment (2). 
Regardless, the need to effectively reduce the overall prevalence and the costly 
outcomes associated with hypertension is paramount.  
Hypertension is strongly linked with risk of cardiovascular disease (CVD) [22] 
and stroke as well as other chronic conditions including cerebrovascular disease, 
ischemic heart disease, and renal failure (23). In 2005, research suggests that 
approximately 400,000 of the 2.5 million deaths (~16% of total deaths) in the United 
States were associated with high blood pressure (1). More recently, between 2007 and 
2010 the American Heart Association reports estimates that 33% of adults ≥ 20 years 
old had hypertension (24). Numerous physiological and genetic factors influence blood 
pressure; yet, dietary factors may have the most substantial effect on maintaining 
homeostasis of blood pressure. Many nutrients and herbal preparations have been 
shown to influence blood pressure; however, three essential minerals, potassium, 
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magnesium, and sodium, are particularly important in regulating and maintaining 
healthy blood pressure (18-20). This review will (1) briefly outline the biological 
mechanisms involved in blood pressure homeostasis; (2) examine the physiological and 
genetic factors that influence risk for hypertension; and (3) discuss dietary factors that 
can reduce blood pressure, focusing primarily on the roles of sodium, potassium, and 
magnesium in blood pressure control.  
Biological Factors 
Kidney’s role in blood pressure 
Regarding the etiology of hypertension, an important biological system to 
consider is the urinary system and the vital role that the kidneys serve to regulate intake 
and outputs of the said minerals being investigated. Generally speaking, excessive 
sodium intake equates to the kidneys working excessively to rid the body of what is not 
needed. The kidneys’ “salt handling” ability is believed to be a primary factor for 
overall cardiovascular health (25). For instance, kidney transplant recipients who were 
hypertensive and previously diagnosed with terminal nephrosclerosis (i.e. progressive 
hardening of the kidney blood vessels) consistently experienced decreased blood 
pressure, reaching normal ranges after receiving a kidney from normotensive donors 
(26).   
From 1900 to modern day, all antihypertensive treatment methods either 
directly or indirectly affect renal sodium handling (27). Treatment methods including 
pharmacotherapy and even the earlier practice of sympathectomy all affect sodium 
handling of the kidneys either directly by inhibiting renal transport proteins, or 
indirectly by regulation of endocrine/neuroendocrine pathways (27). One major 
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contributor to renal physiology and blood pressure research, Dr. Arthur Guyton, 
suggests that long-term changes in blood pressure occur primarily from the kidney’s 
diminishing ability to excrete sodium. Decreased ability of the kidneys to excrete 
sodium leads to greater retention of sodium and subsequently increases in extracellular 
fluid volume, resulting in elevated blood pressure (28).  
Prolonged elevated blood pressure induces progressive and subtle renal micro-
vascular injury. One large-scale observational cohort study, including 4,365 older 
adults, investigated the individual associations of each blood pressure component (i.e. 
systolic, diastolic, and pulse pressure) with declining renal function (29). Glomerular 
filtration rate (GFR) was used as an indicator of renal function; measured at baseline, 
year 3, and at year 7. Increased diastolic blood pressure was not significantly associated 
with decreasing renal function; however, both systolic blood pressure and pulse 
pressure were significantly associated with renal function. For every10-mm Hg increase 
of systolic blood pressure and pulse pressure, there was a faster decline in GFR by 0.13 
ml/min/year and 0.15 ml/min/year, respectively (29).  
The intricate renal endocrine mechanisms implicated in salt handling and 
hypertension entail interactions among a variety of hormones. Some of these hormones 
are renin, angiotensin II, aldosterone, atrial natriuretic peptide (ANP), and antidiuretic 
hormone (ADH). Primarily, it is the effects on peripheral vascular resistance by which 
these hormones induce changes in blood volume and diameter of blood vessels, 
ultimately affecting mean arterial blood pressure. Dysfunction of these hormones has 
been proposed as a result of genetic predisposition and addressing such hormonal 
imbalances has been the primary target of pharmacotherapy for hypertension (30).  
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Fluctuations of blood pressure hormones often occur in response to changes in 
blood volume. Select blood vessels have volume receptors that detect fluctuations in 
blood volume and consequently either contract or stretch, which equates to changes in 
sympathetic tone of the blood vessels (31). The kidney’s role in regulating blood 
pressure is primarily the result of the three hormones renin, angiotensin, and 
aldosterone; commonly referred to as the renin-angiotensin-aldosterone system [RAS] 
(32).  
The ability of the kidneys to regulate blood pressure is illustrated nicely with the 
efficaciousness of common blood pressure drugs such as angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin receptor blockers (32), which all act by 
regulating renal hormones. In response to decreases in blood pressure, the sympathetic 
nervous system reacts by secreting renin. The enzyme renin works on a plasma protein 
called angiotensinogen by cleaving off a portion called angiotensin I. ACE works by 
converting angiotensin I to angiotensin II, which is a hormone that has a variety of 
effects on kidney function and blood pressure (31). Angiotensin II causes 
vasoconstriction resulting in increased blood pressure. Additionally, angiotensin II 
stimulates: sodium and water reabsorption, sense of thirst, and secretion of both 
aldosterone and antidiuretic hormone that promotes water retention (31). ACE 
inhibitors work by decreasing the amount of angiotensin II produced. The dysregulation 
of these RAS hormones have a direct and often unnoticed impact on blood pressure.  
Aldosterone is secreted in response to increased renin in the blood vessels and is 
one of the primary hormones that mediate hormonal responses of the kidneys to high 
potassium intakes (33). High dietary intake of potassium increases plasma potassium 
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levels, and has been shown to stimulate aldosterone secretion. Despite this indirect 
kaliuretic effect of increased aldosterone, resulting from high dietary potassium intakes, 
this is only pronounced when aldosterone is at supraphysiological levels (34).  
Antidiuretic Hormone (ADH) secretion by the pituitary gland is stimulated by 
dehydration and elevated blood osmolarity. This hormone works by increasing the 
permeability of the collecting ducts of the nephrons and therefore increasing the 
amount of water that the kidneys replace back in the fluid being filtered and back to 
blood circulation. At supraphysiological levels, ADH causes vasoconstriction and is 
thus sometimes referred to as “vasopressin”. However, ADH primarily functions as a 
safety mechanism to help prevent dehydration and does not normally fluctuate enough 
to be relevant for dietary factors of blood pressure control (31).  
On the contrast, secretion of atrial natriuretic peptide (ANP) from the heart is 
stimulated in response to elevated blood pressure and results in increased excretion of 
salt and water. This natriuretic effect of ANP reduces blood volume and blood pressure 
by several mechanisms. ANP decreases blood pressure by dilating the afferent arteriole 
and constricting the efferent arteriole, which results in increased glomerular filtration 
rate; inhibiting secretion of antidiuretic hormone (ADH), renin and aldosterone; and by 
inhibiting sodium reabsorption by the collecting duct (31).  
Arterial Stiffness and the Augmentation Process 
Research demonstrates that arterial stiffness and hypertension are positively 
associated with age (35, 36). With aging, the composition of structural proteins (i.e. 
collagen and elastin) changes and has a direct effect on stiffness of arteries. 
Particularly, these changes occur in major “conduit arteries”, including the aorta, iliac, 
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carotid, femoral, and brachial arteries (35). The primary function of these conduit 
arteries is to serve as a compliant and low resistant pathway from the heart to supply 
blood to all of the living tissues. Healthy, pliant conduit arteries are necessary 
considering that the distension of the aortic artery upon the contraction of the heart, acts 
in a rhythmic manner called “pressure pulse wave” (35). The elastic fibers that 
comprise arteries serve to help deliver blood to distal tissues − in a ‘ripple-like’ 
manner− without requiring excessively elevated systolic blood pressure. Therefore, the 
stiffer the conduit arteries, the greater the systolic pressure needed in order to produce 
adequate blood flow (35). 
The structural changes in conduit arteries are primarily related to the changing 
proportional composition of elastin and collagen fibers. Compared to more distal 
arteries and arterioles, the more proximal the arteries to the heart, the greater the 
proportion of elastin to collagen fibers. With ageing, elastin fibers are fragmented and 
degraded, and ultimately not sufficiently regenerated. This structural degradation is 
superseded by increased proportion of considerably less-compliant collagen fibers (36). 
A recently published randomized, placebo-controlled crossover study 
investigated the effects of sodium and potassium supplementation, independently, on 
blood pressure and arterial stiffness (15). This study included 36 untreated pre-
hypertensive (69% subjects had baseline SBP > 140) adults, and subjects followed a 
controlled diet with relatively low sodium and potassium for a 1-week run-in period. 
Subjects were then randomly assigned to a 4-week interval supplementation of 3,000 
mg sodium, 3,000 mg potassium, or a placebo, and then complete the corresponding 
other two 4-week intervals subsequently. At baseline and at each 4-week visit, 
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measures of office blood pressure, 24-hour ambulatory blood pressure and indicators 
(i.e. pulse wave velocity and augmentation index) of arterial stiffness were assessed. 
The active intervention of sodium resulted in a significant increase in office blood 
pressure by 7.5/3.3 mm Hg and 24-hour ambulatory blood pressure by 7.5/2.7 mm Hg. 
Potassium supplementation resulted in a significant decrease in 24-hour ambulatory 
blood pressure by 3.9/1.6 mm Hg. However, sodium or potassium supplementation had 
no significant effect on pulse wave velocity or augmentation index (15).   
Genetic factors 
Salt handling is largely dependent on genetic predisposition. Genetic research 
has identified numerous genetic mutations in severely hypertensive families, which are 
responsible for encoding proteins involved in regulating ion channels and transporters 
in the nephrons of the kidneys. These genetic mutations affect cellular transport of 
minerals, increase renal reabsorption and blood volume, and ultimately lead to an 
increase in blood pressure (26). Although these genetic mutations (“single nucleotide 
polymorphisms”) do not imply a causative factor for hypertension, they must be 
considered because of the impact on individual predisposition to hypertension.  
Regarding the important role that the renin-angiotensin-aldosterone system 
(RAS) (discussed earlier) has on regulating blood pressure, variants of the genes that 
encode the elements of this system have been hypothesized as key factors for the 
genetic predisposition of hypertension. Ji and colleagues conducted a case-control study 
that examined the association between genetic variants (i.e. polymorphisms) that 
encode RAAS genes and hypertension (37). This study compared 905 hypertensive 
cases to 905 normotensive controls among the Han Chinese population. It was reported 
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there was significantly higher Body Mass Index (BMI), serum triglycerides and total 
cholesterol in the hypertensive group, compared to the 905 controls. Further, this study 
identified multiple polymorphisms in the RAAS genes that may indicate genetic 
susceptibility to hypertension. From the 41 single nucleotide polymorphism (SNPs) that 
were genotyped, six were demonstrated to associate with hypertension. More 
importantly, the hypertensive cases had significantly higher odds ratio of having these 
six identified SNPs. Given that this study was conducted with a large and relatively 
homogenous sample of the Han Chinese, the findings of this study are unique because 
they limit possible influence of environmental factors and confounders for 
hypertension.  However, the unique design of this study also suggests these findings 
may be limited to those of the Han Chinese population and not generalizable to the 
citizens of the United States. The results of Ji and colleagues study suggest that genetic 
polymorphisms do have an impact on blood pressure regulation and individual 
susceptibility for hypertension.  
Olives and colleagues conducted a study using data from National Health and 
Nutrition Examination Survey (NHANES), a nationally representative cross-sectional 
survey (2). NHANES collects data on markers of self-reported health every two years, 
Olives et al used data from 1999-2008. Compared to white, Hispanic and other races, 
blacks tend to have the greatest prevalence of hypertension in the United States. 
However, according to NHANES data, black Americans also have the greatest 
awareness and treatment of hypertension compared to other races (2). One study 
investigated the effects of variant potassium intake levels on blood pressure and sodium 
retention in healthy adults, between 21-35 years old, with normal renal function (38). It 
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was reported that black subjects had significantly less excretion of both potassium and 
sodium after a potassium-supplemented diet, as compared to white subjects. 
Additionally, black subjects had significantly less excretion of sodium after following a 
potassium-restricted diet as compared to white subjects. However, this study is limited 
by the small size of the sample; there were only 21 subjects (11 black, 10 white). 
High sodium intakes in blacks are associated with greater increases in blood 
pressure as compared to whites. This effect is partially explained by the finding that 
blacks have fundamental differences in the kidney’s ability to maintain sodium 
homeostasis (39). Luft and colleagues investigated sodium sensitivity in normotensive 
subjects who were deemed at higher risk for developing hypertension (39). This study 
focused on black subjects, primarily those at least 40 years of age and who were related 
(first-degree) to hypertensive patients. Furthermore, this study documents lower plasma 
levels of renin and aldosterone in blacks compared to whites (p <0.05).  This is an 
interesting finding considering that renin and aldosterone both elevate blood pressure. 
Dietary Factors  
Current Antihypertensive Paradigm- The DASH Diet 
Many studies identify dietary factors that are important for managing blood 
pressure. Factors to consider include: sufficient intakes of fruits, vegetables, and low-
fat dairy; inclusion of fish, poultry, whole grains, and nuts; and only modest intakes of 
sugar-sweetened beverages, meats, total fats, and saturated fats (8, 9, 40). These dietary 
factors are encompassed within the tenets of the DASH (Dietary Approaches to Stop 
Hypertension) Diet, which is an internationally accepted remedy for attenuating 
hypertension and has been proven effective in studies for nearly two decades (23).  
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The DASH Diet is incorporated within guidelines for managing blood pressure 
from the U.S. Government, the International Society of Hypertension (ISH), and the 
World Health Organization (WHO) (23). Although the DASH Diet offers a definitive 
and effective tool for managing hypertension, the public is often reluctant to initiate or 
maintain significant dietary changes, even for the sake of bettering individuals’ health. 
One study suggested that the degree of adherence to the DASH Diet was relative to the 
effect that it had on reducing blood pressure (41). This study reaffirmed the notion that 
the DASH diet is particularly effective when compliance to dietary guidelines is high, 
and only moderately to non-effective when adherence is minimal. The finding that a 
common lack of adherence to an effective therapeutic model seems to imply that a 
simpler and less didactic dietary approach would facilitate greater success of managing 
blood pressure for such individuals who do not comply well with multiple instructions 
and guidelines.  
Distinguishing characteristics of the DASH Diet are the favorable proportion to 
fruits, vegetables, legumes, and low-fat dairy products; moderate levels of saturated fats 
and minimal amounts of red meats and sweets/added sugars; as well as inclusion of 
whole grains, poultry, fish, and nuts (7). The DASH Diet also limits saturated fats, 
cholesterol, and salt (9). Comparing the DASH diet to the “Standard American Diet” 
(SAD Diet) (42), a notably contrasting characteristic is the proportion of dietary 
minerals consumed. For instance, the SAD Diet includes highly refined and processed 
foods. Such processed food and food products tend to be high in sodium and low in 
potassium and magnesium. On the contrast, the DASH dietary pattern includes foods 
that are rich in potassium, magnesium and calcium. Dietary Guidelines for Americans 
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in 2015 recommend limiting sodium intake to less than 2,300 mg/day. This Tolerable 
Upper Limit (UL) of 2,300 mg/day, established for sodium was based on the finding 
that excessive sodium intake promotes high blood pressure and may promote further 
decline in individuals with kidney disease (43). However, average intakes of sodium 
exceed this recommendation by approximately 50% with estimates of average intakes 
exceeding 3,330 mg/day of sodium (44). This discrepancy of mineral intakes between 
the two diets is concerning and it was expressed with the Institute of Medicine’s release 
of a report in 2010 titled Strategies to Reduce Sodium Intake in the United States. 
Appel and colleagues (8) succinctly conclude a major problem that one primary 
challenge we currently face is to develop and implement more effective strategies for 
public health and clinical practice that promote sustainable dietary changes to prevent 
and treat hypertension. This is an enormous task, requiring cooperative development 
and implementation among government officials, healthcare providers, researchers, and 
the general public (8). Ultimately, convoluted problems do not yield quick solutions; 
alternative solutions must be considered for greater control and prevention of 
hypertension.  
Effects of Minerals on Blood Pressure 
Interrelationship of Sodium and Potassium  
The biological interrelationship of sodium and potassium and their effects on 
blood pressure was first investigated in the 1920’s. Specifically, the natriuretic effect of 
potassium salts (e.g. potassium citrate, potassium bromide and potassium chloride) and 
the hypertensive effects of sodium were identified (19). Furthermore, this early 20th 
century study discussed the likelihood of potassium-poor and sodium-excess diets 
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being the primary cause in rising prevalence of hypertension in North America. 
Considering that sodium is the most abundant extracellular ion and that potassium is the 
primary intracellular ion, these two essential minerals should first be explored 
simultaneously to help elucidate antihypertensive mechanisms. 
Evidence and estimates of ancestral salt intake, suggest that in ancient 
civilizations and even in non-industrialized regions of the globe today, individuals 
subsist on low sodium intakes such as <1g/day (compared to intakes exceeding 3.3 
grams/day in the United States). Even more relevant is the fact that many of these non-
industrialized and isolated populations also generally lack hypertension (25). Ancestral 
and even modern non-industrialized populations rely on non-processed foods that are 
generally lower in sodium and rich in potassium among other essential minerals such as 
magnesium. In contrast, sodium-rich diets − that are primarily based on processed 
foods are deficient in potassium and magnesium − are common in industrialized nations 
like the United States.  This stark contrast of mineral intake in industrialized nations 
occurred primarily over the past century as the result of potassium losses from 
processing foods and artificial salting for use as a preservative and to increase 
palatability of foods. (44).  
Cook and colleagues (45) measured the combined effects of potassium and 
sodium intake on later development of cardiovascular disease (CVD). This 10-15 year 
trial included information from 2,275 participants and included a total of 193 CVD 
events. Although there were no significant trends observed in CVD risk between 
quartiles of sodium and potassium excretion individually, there was a significant trend 
between quartiles of the sodium-potassium ratios (RR= 1.00, 0.84, 1.18, and 1.50, p-
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trend=0.04) (45). These findings suggest that the ratio of sodium to potassium is a 
greater determinant of hypertension and CVD than intake levels of sodium or 
potassium alone. 
Further, one major international study investigated the relationship between 
sodium and potassium excretion in 10,079 adults aged 20-59 and found that the ratio of 
sodium to potassium was more strongly associated with both systolic blood pressure (p 
< 0.001) and diastolic blood pressure (p < 0.05) than sodium or potassium alone (46). 
Conducted from 1988-1990, this ‘Intersalt’ study demonstrated a significant and 
positive relationship between sodium levels and both systolic and diastolic blood 
pressure (46). The Intersalt study was a novel undertaking since it used standardized 
methodology at 52 separate locations in 32 countries. However, the study was limited 
by 24-hour urine collection used to estimate electrolyte excretion. Thus, within-person 
variability was a major limitation of this study.  
There is an abundance of evidence suggesting the hypertensive effects of 
excessive dietary sodium intake (7-9, 46). One prominent cohort study conducted in 
Japan found a positive association between sodium intake and mortality from stroke. 
Specifically, comparing those in the highest quintile (3,105 ± 414 mg/day) to those in 
the lowest quintile (1,150 ± 345 mg/day) of sodium intake, there was a 55% greater risk 
of total stroke (47). The estimated mean sodium intake from food frequency 
questionnaire was 1,909 mg/day; however, the estimated mean intake was 3,841 
mg/day from four 3-day dietary records included in the validation study.  In this same 
cohort, there was an inverse association between potassium intake and mortality from 
total cardiovascular disease. Although that study is a bit outdated, being conducted 
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from 1988-1990, these findings are notable because of the large study population 
(58,730 Japanese men and women) with subjects generally consuming high intakes of 
dietary sodium comparable to the average American intake.  
Current and past literature richly reflects the importance of consuming adequate 
potassium while simultaneously decreasing sodium intake to reduce hypertension and 
associated cardiovascular outcomes. Therefore, an alternative and indirect approach to 
decreasing sodium levels is to promote sodium excretion; which leads to the 
importance of the natriuretic effect of potassium and adequate dietary consumption of 
potassium as a preventive means from hypertension.  
Potassium 
Considering the multiple roles potassium serves that are related to blood 
pressure homeostasis, the primary antihypertensive mechanisms to explore are the 
induced vascular relaxation and the natriuretic effect of potassium. The 
antihypertensive effects of potassium were first identified nearly a century ago, and 
were applied in clinical settings thereafter (19). One widely known clinical practice of 
promoting potassium intakes was that of Dr. Walter Kempner at Duke University in the 
1940’s. Despite concerns of nutrient deficiencies, Dr. Kempner’s Rice-Fruit Diet 
demonstrated success with treating congestive heart failure and severe hypertension 
(48). Hallmarks of Kempner’s Rice-Fruit Diet include an abundance of potassium and 
extremely low levels of sodium. This diet was extensively used throughout the 1940’s, 
and was not only successful at managing hypertension, but also proved effective at 
reducing obesity, stopping hemorrhaging, heart and kidney failure, and even attenuating 
diabetes and arthritis.  
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In 2003, the National High Blood Pressure Education Program Coordinating 
Committee (JNC 7) recommended that adequate consumption of dietary potassium 
(3,500 mg/day) be suggested for primary prevention of hypertension. The American 
Heart Association published new guidelines in 2006 that recommended increasing 
potassium intake to 4,700 mg/day (8). However, because of an insufficiency of dose-
response trials with potassium supplementation, there have yet to be any specific levels 
of dietary potassium recommended for those who are aiming to manage hypertension 
(8).  
Research suggests salt sensitivity is attenuated, and can even be alleviated when 
supplemental potassium intake levels are sufficient. That is, potassium supplementation 
has demonstrated an impressive, dose-dependent inhibitory effect on sodium sensitivity 
in normotensive individuals (16). Sodium sensitivity was defined as an elevation in 
mean arterial blood pressure (≥ 3 mm Hg) after a salt loading administration. Changes 
in mean arterial blood pressure (MAP) after salt loading ≤ 10 mm Hg were considered 
moderate salt sensitivity; changes >10 mm Hg were considered severe salt sensitivity. 
Morris and colleagues used a metabolically controlled diet protocol, starting with a 
basal low-sodium (approximately 345 mg/day [15 mmol/day]) and moderately deficient 
potassium (approximately 1,176 mg/day [30 mmol/day]) diet for 6 weeks, compiling 
data from 41 case studies (38 healthy normotensive men). During weeks 3-6, sodium 
chloride was loaded (5,750 mg/day [250 mmol/day]); during weeks 4-6, potassium was 
supplemented at mid- or high-normal levels (approximately 2,745 mg and 4,704 mg, 
respectively [70 and 120 mmol/day, respectively]). The mid-normal level of potassium 
decreased moderate salt sensitivity, while the high-normal level eliminated moderate 
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sodium sensitivity and decreased severe salt sensitivity. Of importance, this study 
included healthy normotensive adult males; mostly black males (24 blacks, 14 white). 
These findings are important considering that black males are more salt sensitive and 
have a higher prevalence of hypertension (16). Furthermore, this research reinforces the 
notion that it is the proportional intake of potassium to sodium that is more of a 
determinant of blood pressure than the individual intakes of potassium or sodium.  
Vascular effects of Potassium 
Indices of vascular function are commonly used measures of risk of stroke and 
heart diseases. One tool to assess vascular function is flow-mediated dilation (FMD). A 
noninvasive measure, FMD utilizes ultrasound waves to measure endothelial function 
and is used as an indicator of mortality risk from cardiovascular diseases. In a 
prospective study, Gokce and colleagues concluded that in patients with peripheral 
artery disease, diminished FMD of the brachial artery is a predictor of cardiovascular 
incidences (49). In a randomized crossover study, Blanch et al found that, compared to 
a low potassium diet, a high potassium diet improved postprandial FMD, which 
indicates improved endothelial function (50).   
Zhou et al (51) investigated effects of vascular changes on hypertensive Dahl 
salt-sensitive rats fed various diets: a high-sodium diet, high-sodium/potassium-
supplemented diet, or a standard rat chow diet. Zhou and colleagues reported 
significant increases in blood pressure among the rats fed a high-sodium diet. This 
hypertensive effect was diminished by potassium supplementation. Further, 
supplementation of potassium enhanced vascular relaxation and increased urinary 
excretion of nitrite (NO2-) and nitrate (NO3-). It was deduced that vascular relaxation 
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observed in the potassium-supplemented rats was the result of increased endothelial 
nitric oxide (NO). Although the mechanism of increased NO resulting from potassium 
supplementation remains unclear, it was suggested that this might be the result of 
increased production of NO in the endothelial cells (51).   
Endothelial cells produce NO and production of this signaling molecule is 
important because of the vasodilator effects, which result in reduced vascular resistance 
and blood pressure (52). Taddei and colleagues investigated whether supplementation 
of intra-arterial potassium affected acetylcholine-induced vasodilation in hypertensive 
and normotensive patients (52). This study found that infusion of potassium enhances 
the acetylcholine-dependent vasodilation of the endothelium, thus decreasing peripheral 
resistance and blood pressure. It was reported that potassium administration enhanced 
endothelial function in hypertensive patients, but not in normotensive patients. 
However, one limitation of this study is the modality of potassium administration. The 
acute intravenous administration of potassium may not have the same effects as dietary 
supplementation of potassium. Therefore, these findings may not be relatable to 
supplementation of dietary potassium; though they do help elucidate mechanisms by 
which increased potassium intake, by any mode of ingestion, reduces blood pressure.  
Natriuretic effect of Potassium 
Long-term high potassium dietary intakes are shown to increase density of 
sodium and potassium secretory channels in Sprague-Dawley rats (53). 
Electrophysiological data on isolated components of the functional units (i.e. nephrons) 
of rat kidneys demonstrate that increased dietary intake of potassium results in 
upregulation of active potassium and sodium channels, ultimately increasing urinary 
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excretion of both minerals (53). Given that this natriuretic/kaliuretic effect is known to 
result from long-term high potassium intake, Palmer and colleagues examined whether 
these channel fluctuations were implicated in the short-term, daily maintenance of 
potassium homeostasis. Sprague-Dawley rats in the treatment group were administered 
a high-potassium diet (10% potassium chloride) for 6 hours. After just 6 hours, the 
density of sodium channels in the cortical collecting tubules was 0.08 channels/µm2 for 
controls and 1.0 channels/µm2 after high-potassium diet. Despite the potential of this 
finding being a mechanistic explanation for natriuresis, there are limitations to these 
findings. Firstly, only a small segment of the nephron, the cortical collecting tubule, 
was investigated and therefore does not account for other segments of in the nephrons 
where secretion and reabsorption occur. Further, these studies were conducted 
postmortem and it is presumed that the cells remain polarized and that the documented 
clustering of sodium and potassium channels was not possibly the result of slight 
physical damage to cells during isolation of the tissues.  
The natriuretic effect of potassium is directly related to the intake of sodium. 
One study found that the greater the sodium intake was, the greater the subsequent 
excretion of sodium following potassium supplementation (54). Van Buren and 
colleagues studied the effect that the same dosage of potassium load (approximately 
3,920 mg [100 mmol]) had on varying sodium intake levels and the subsequent urinary 
excretion of minerals. Compared to the low and moderate levels of sodium intake, the 
subjects with the highest level of sodium intake demonstrated the highest level of 
sodium excretion after potassium loading. Additionally, this study demonstrated that in 
those who had a sodium-restricted diet (i.e. low sodium levels), potassium 
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administration actually caused retention of sodium rather than natriuresis. These 
findings further illustrate the interdependent effects of potassium and sodium and 
highlight the importance of adequate potassium intake in those who consume high 
sodium diets and have high blood pressure.  
Effects of potassium deficiency 
Inadequate levels of dietary potassium cause the kidneys to reserve sodium and 
water, resulting in increased blood volume and blood pressure. Gallen and colleagues 
investigated the effects of potassium-restricted diets on sodium retention and blood 
pressure including 21 subjects with normal renal function and taking no medications. 
This study concluded that after restricting potassium intake, healthy/normotensive 
participants with normal renal function and taking no medications increased renal 
retention of sodium, chloride, and potassium; ultimately leading to expansion of blood 
volume and increased blood pressure (38). Additionally, this study found that the 
antinatriuretic effect of a potassium-restricted diet is immediate as this was evident in 
the first 24 hours of urinary electrolyte excretion. This effect was gradually dissipated 
over the subsequent 8 days.   
Krishna and colleagues conducted a double blind, randomized, crossover study 
investigating the effects of potassium restriction on blood pressure (55). This study 
included 12 hypertensive subjects that were placed on a 10-day isocaloric diet, who 
also maintained a constant intake of sodium. Compared to the higher potassium group, 
the group that adhered to a potassium-depleted diet had significantly higher systolic and 
diastolic blood pressure (7 mm Hg and 6 mm Hg, respectively). Converse to the 
natriuretic effects of potassium discussed earlier, the potassium-restricted group had 
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significantly decreased excretion of sodium. Therefore, a potassium deficient diet 
promotes retention of sodium, which may exacerbate essential hypertension.  
These findings that a low potassium diet promotes retention of sodium and 
increased blood volume and pressure is important considering that the average 
potassium intake in the United States is far below the Adequate Intake (AI). Self-
reported dietary data gathered from the National Health and Nutrition Examination 
Survey (NHANES III), adult men average about 2,900-3,200 mg/day and adult women 
average about 2,100-2,300 mg/day potassium. Even more concerning is the estimate 
that only about 10% of men and 1% of women are consuming at least the AI of 
potassium (4,700 mg/day) (8).  
High-potassium, low-sodium salt substitutes 
More recently, a randomized controlled trial published in 2014 demonstrated 
efficacy of a low-sodium, high-potassium salt substitute reducing blood pressure among 
a hypertensive Tibetan population (56). Similar to Americans, Tibetans have a high 
prevalence of hypertension and have estimated intakes of sodium exceeding four times 
the World Health Organization’s (WHO) recommended intake. This 3-month 
intervention included 282 Tibetans aged 40 years and above and included subjects who 
reported already taking antihypertensive medications in the prior month. The salt-
substitute treatment was comprised of 65% sodium chloride, 25% potassium chloride, 
and 10% magnesium sulfate; the control group received three months worth of 100% 
sodium chloride to prepare foods with. Both the treatment and control groups had 
marked decreases in systolic and diastolic blood pressure, however the treatment group 
had statistically significant greater decreases in both systolic and diastolic blood 
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pressure. Compared to the control group, the net reduction of blood pressure in the 
treatment group was -8.2 mm Hg systolic and -3.4 mm Hg diastolic (all p <0.05) (56). 
Another randomized, double-blinded study investigated the feasibility and 
hypotensive effect of replacing table salt with an alternative salt (“Smart Salt”) rich in 
potassium and magnesium (57). This study included 45 subjects and lasted 8 weeks. 
Comparing the subjects’ 24-hour daily urinary sodium levels, there were significant 
decreases in the treatment group (those who used Smart Salt®) compared to those in the 
regular salt (control) group. Additionally, it was reported that the Smart Salt group 
observed a mean decrease of 7.5 ± 10.1 mm Hg in systolic blood pressure (SBP) and a 
mean decrease of 2.7 ± 4.5 mm Hg in diastolic blood pressure (DBP). This finding was 
interesting since the regular salt (control) group observed a marginal increase in blood 
pressure. That is, 3.8 mm Hg higher in SBP and 1.5 mm Hg higher in DBP. However, 
there was only statistical significance between these two groups’ SBP values at week 3 
(p = 0.028) and not a statistically significant (p = 0.076) difference upon finishing the 
8-week intervention. Smart Salt® is novel because it offers consumers a dietary product 
to replace table salt while reducing salt intake, all while purportedly not sacrificing 
flavor that consumers come to expect with table salt. That is, Smart Salt® is composed 
of 50% sodium chloride, 25% potassium chloride, and 25% magnesium salts (57). 
Magnesium 
Magnesium’s biological roles are diverse, and intracellular magnesium is 
needed to facilitate over 300 different enzymatic reactions (43). More specifically, this 
essential mineral is needed for proper metabolism of carbohydrates, fats, and protein. It 
is also necessary for the synthesis of nucleic acid (DNA), activation of amino acids, and 
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transcription of DNA and RNA. Due to the vast number of functional roles magnesium 
has in biochemical reactions, there are numerous mechanisms by which magnesium 
may have direct or indirect influence on blood pressure.   
Like potassium, the hypotensive effects of magnesium have been known and 
used in clinical settings for approximately a century (20). Pharmacological doses of 
magnesium sulfate were first used to induce hypotension among hypertensive patients 
in clinical settings in 1925 (20). Due to its role in numerous biological processes, 
magnesium has different mechanisms of action in blood pressure management than 
potassium. A primary mechanism to consider is that magnesium promotes dilation of 
the blood vessels (18).  
Regarding more preventive approaches to high blood pressure, a meta-analysis 
conducted in 2002 which investigated the effects of magnesium supplementation on 
blood pressure concluded the detection of a dose-dependent response to reducing blood 
pressure among normotensive and hypertensive persons (58). This meta-analysis 
compiled 20 different randomized trials and 14 out of these 20 were investigating 
hypertensive populations, while only 6 of these studies investigated effects in 
normotensive populations. Magnesium dosages in the included studies were between 
10-40 mmol/day (i.e. approximately 243 mg – 972 mg). The dose-dependent effect 
from the meta-analysis overall was reported that for each increase of 10 mmol/day of 
magnesium, there was a decrease of 4.3 mm Hg systolic BP (95% CI 6.3 to 2.2; P < 
.001) and of 2.3 mm Hg diastolic BP (95% CI 4.9 to 0.0; P = .09). Considering the 
large range of magnesium dosages and difference in populations’ blood pressure 
ranges, there were only marginal yet notable decreases in blood pressure. 
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Effect of magnesium on vascular tone 
Magnesium is a vasodilator, and therefore lowers blood pressure by decreasing 
peripheral resistance (18). It is proposed that magnesium’s role in controlling cellular 
sodium pump (on all cell membranes) activity has a direct influence in transporting 
sodium and potassium across cell membranes, which affects blood pressure regulation. 
Variant levels of extracellular magnesium induce such effects. Magnesium also affects 
the reactivity of the cells by influencing the amount of sodium and calcium that are 
exchanged (18). Ultimately, it is this altered reactivity that affects vascular tone and 
consequently, blood pressure.  
Although magnesium is not precisely involved in the biochemical course of 
vascular contraction, it is a calcium antagonist, and has an indirect role on vascular 
contraction that must be further explored. Kh and colleagues measured the effects of 
magnesium supplementation on blood pressure and calcium handling in hypertension-
induced rats (59). Deoxycorticosterone acetate (DOCA) was used to induce 
hypertension in the rats of the treatment group, to compare the effects of magnesium 
supplementation to those in the control group, who were normotensive. In the 
magnesium-supplemented/DOCA-induced hypertension group, rats had significantly 
lower concentrations of intracellular calcium (59). This finding is important because of 
the role that calcium has in maintaining vascular tone.  
A study in 2010 investigated the effects that oral magnesium supplementation 
had on vascular function in elderly diabetics (17). After one month of supplementation, 
those in the treatment group had significantly improved endothelial-dependent 
vasodilation, while there were no significant changes in vasodilation for those in the 
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control group. It must be noted that the study population was composed of elderly (i.e. 
≥ 65 years old) diabetic patients. There were 30 subjects in the treatment group, who 
took 368 mg/day of magnesium (4.5 g/day magnesium pidolate). There were no 
significant decreases in blood pressure, but endothelial-dependent flow-mediated 
dilation (post-ischemic, induced from tourniquet) of the brachial artery improved in the 
treatment group. Specifically, the significant vascular changes measured in the 
treatment group went from 3.3% ± 3.6% to 8.4% ± 3.9% (p < 0.01) (17). There were no 
significant changes within the control group. The results of this study demonstrated that 
magnesium supplementation in elderly diabetic patients resulted in improved 
endothelial function of the brachial artery.  
These findings are generally congruent with other studies investigating 
magnesium-induced vasodilation. This relaxation effect of the blood vessels is 
purportedly mediated by the release of nitric oxide (NO) from the endothelium (60). It 
is NO acting as a mediator, which promotes vasodilation and in turn decreases 
peripheral resistance in blood arteries, and ultimately decreases blood pressure (61). 
Sodium retention from high sodium intake lowers biological synthesis of NO. Fujiwara 
and colleagues (61) illustrated this by showing that following increased intakes of salt 
(“salt loading”), plasma levels of NOx (nitrate + nitrite) decreased accordingly and 
were increased after subsequent salt restriction. However, a limitation of this study was 
that it included only hypertensive patients and these findings may not be applied to pre-
hypertensive individuals.  
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Magnesium, sodium, and insights of Deep Sea Water 
One study measured the effects of oral magnesium supplementation in 
hypertensive populations and reported that 1g of magnesium oxide/day (600 mg 
Mg/day) lead to a significant decrease in both blood pressure and blood lipid 
concentrations (18). The 4 weeks of magnesium supplementation resulted in a decrease 
of mean blood pressure from 111±6 to 102±6 mm Hg (p < 0.001); the subsequent 4-
week placebo resulted in increase of mean blood pressure back up to 108±5 mm Hg (p 
< 0.001). Another interesting finding of this study was that those with higher sodium in 
erythrocytes (red blood cells) had greater hypotensive effects after treatment of 
magnesium. This finding reinforces the notion that those with higher intakes of sodium 
will have greater hypotensive responses to supplementation of magnesium (in addition 
to potassium). However, both the small sample size (only 21 males) and including only 
hypertensive individuals limit data interpretation from this study.  
With the recently passed Affordable Healthcare Act emphasizing the 
importance of primary prevention of diseases, there is a greater focus on 
prehypertension.  In 2013, Rodriquez-Moran and colleagues investigated the 
association between low serum magnesium values and prehypertension in otherwise 
healthy adults (62). This was a cross-sectional study that included 175 healthy men (n = 
59) and women (n = 116), aged between 20-65 years. There was a statistically 
significant difference in serum magnesium levels between the prehypertensive group 
and the group without prehypertension. Those with prehypertension had lower 
magnesium levels and higher triglyceride levels than non-prehypertensive individuals.   
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Recent research brings greater attention to the mineral composition and 
potential salubrious effects of deep-sea water. Although the primary mineral in surface 
seawater is sodium and includes lesser amounts of magnesium and potassium, deep-sea 
water (DSW) has a predominant composition of magnesium and potassium. A recent 
study investigated the effects that DSW had on blood pressure and blood lipids in 
spontaneously-hypertensive rats (63). The seawater mineral was obtained from the 
Pacific Rim off of Taiwan and the composition was primarily magnesium. Three 
different concentrations of diluted DSW were composed for the treatment groups: 3.75 
mg Mg/kg DSW (0.1x DSW); 37.5 mg Mg/kg DSW (1 x DSW); and 75 mg Mg/kg 
DSW (2 x DSW). Just half way through the 8-week study, there were significant 
decreases in systolic and diastolic arterial blood pressure in two groups (1 x DSW and 2 
x DSW) compared to the control group. At the end of the 8-week study, even the lowest  
(0.1 x DSW) of the three concentrations resulted in significant decreases in both 
systolic and diastolic arterial pressure compared to the control group. Furthermore, the 
two stronger concentrations of DSW resulted in significantly decreased cholesterol 
levels and lipid accumulation in the liver. This study is novel because of the unique 
utilization of an abundant natural resource (i.e. DSW) and the resulting data that gives 
further credence to the claim that desirable and proportional intake of essential minerals 
is a key factor in blood pressure management.  
Research Deficiencies  
The antihypertensive mechanisms of the primary dietary remedy for 
hypertension, the DASH Diet, have yet to be fully elucidated (10, 40). Among the most 
commonly proposed mechanisms is the increased nitric oxide bioavailability that has 
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been observed from the DASH Diet (40). Additionally, the natriuretic effect associated 
with the diet is commonly associated with concurrent high intake levels of potassium, 
magnesium, and calcium (64). However, more randomized controlled trials with larger 
sample sizes and longer follow-up periods and a better understanding of molecular 
pathways are needed to further elucidate the specific mechanisms of the DASH Diet.  
There is inconsistency of findings among different randomized clinical trials 
(RCTs) and meta-analyses, regarding hypotensive efficacy of potassium and 
magnesium supplementation, in various populations. One recent meta-analysis (65), 
published in 2006, investigated the hypotensive effects of potassium supplementation 
and found inconsistent findings between six RCTs. No statistically significant decreases 
in blood pressure were found in the review of six RCTs. The most notable outcome of 
this recent meta-analysis however, was the dissimilarity among the findings of different 
trials. Another limitation of this meta-analysis was that it included studies that had 
minimal duration of follow-up visits and two of the six studies had small sample sizes. 
Therefore, this study concluded that the evidence on potassium supplementation for 
hypertension is inconclusive. In contrast, a less recent and perhaps more significant 
meta-analysis (66) reviewed 20 trials and found a statistically significant decrease in 
both systolic and diastolic blood pressure from potassium supplementation. This article 
concluded that recommending increased potassium intakes should be considered for the 
prevention and treatment of hypertension. However, one major limitation of this review 
was that it included trials with very limited follow-up periods, such as only four days. 
Regarding magnesium, a recent meta-analysis concluded there was not strong 
enough evidence to indicate the usage of magnesium supplementation for adults to 
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manage essential hypertension (67). Deficits of knowledge that impede update of 
magnesium recommendations for those with hypertension and pre-hypertension are 
related to absence of a standard type and dosage of supplement:, short intervention 
trials, and overall heterogeneity of subject populations. However, the antihypertensive 
effects of magnesium may be more pronounced in pre-hypertensive persons rather than 
those with essential hypertension.  
In summary, the most prominent deficit of knowledge pertains to consistency of 
findings. That is, the general lack of uniformity between many of the study designs and 
the populations being investigated makes it challenging to draw strong conclusions 
about the effectiveness and dose-related responses to supplementation of potassium and 
magnesium. This problem is particularly difficult to elucidate because of the synergistic 
effects of the minerals being investigated and because of the great variance between 
intake levels of blood pressure-regulating minerals seen between different population 
groups.  Additionally, due to the many intricate renal mechanisms involved in 
biological balance of the aforementioned minerals, further understanding of precise 
hypotensive mechanisms of potassium and magnesium requires a profound 
understanding of renal physiology.   
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CHAPTER 3 
METHODS 
Subjects and study design: 
Subject selection  
Subjects were considered eligible for the study if they were over 18 years old, 
under 80 years old, had stable medication use, who had mildly/moderately elevated 
blood pressure (i.e. Systolic blood pressure: 115-140 mm Hg and/or Diastolic blood 
pressure: 70-90 mm Hg), and had no unresolved medical conditions. Unresolved 
medical conditions were defined as any medical diagnoses such as food allergies, type 
2 diabetes, thyroid problems and cancer; and that had not already been treated by a 
physician.  
Subjects were excluded if they had any of the following: heart disease, renal 
insufficiency (or other organ pathology), medication use for hypertension, systolic 
blood pressure >140 or <115 mm Hg, diastolic blood pressure >70 or <90 mm Hg, nut 
allergies, or if they were pregnant or lactating. A nut allergy was an exclusion criterion 
because the treatment/placebo was made with peanut butter.  
Recruitment 
Subjects were recruited from a college campus and surrounding community in 
metropolitan Phoenix via online advertisements in winter 2013 and spring 2014. List 
serves were obtained from the Arizona State University campus community. The 
dispersed advertisement informed that this was an 8-week randomized controlled trial 
designed to examine whether a nutrient preparation improves blood pressure in adults 
with mildly to moderately elevated blood pressure (see appendix A). Interested 
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individuals were invited to complete an online screening questionnaire (see appendix 
B). Those who qualified and were still interested in participating were then invited to 
meet with study investigators at Arizona State University (in the Arizona Biomedical 
Collaborative [ABC] building on the Downtown Phoenix Campus) to discuss the trial. 
Each subject provided written consent at the initial visit and the study received approval 
by the Arizona State University Institutional Review Board (see appendices C and D, 
respectively).  
Chewy Bar Treatments 
 Each treatment serving was 18.5 grams, had 77.5 calories, and contained 10 grams 
peanut butter (Jif Natural Peanut Butter, The J.M. Smucker Company, Orville, OH), 5 
grams jelly (Smucker’s Seedless Strawberry Jam, The J.M. Smucker Company, Orville, 
OH), and 2 grams all-purpose (AP) flour (see appendix E). In addition to these base 
ingredients that comprised the placebo recipe, the treatment chewy bar also contained 
217.2 mg potassium (417 mg of Potassium Chloride Powder, NOW Supplements, 
Bloomingdale, IL) and 70.8 mg magnesium (943 mg of MagCitrate Powder, Designs 
for Health Inc, Suffield, CT). All participants were instructed to consume one chewy 
bar each day, at the same time of the day, and to not consume any other drinks (except 
water) or foods at least 30 minutes before or after the chewy bar. Participants recorded 
daily consumption of the chewy bar on a compliance calendar to measure the adherence 
to the prescribed regimen. For ingredient calculations, see Appendix E.  
The mineral dosage values used in this study were based on similar controlled 
trial that used the same dosage values and found significantly lower blood pressure on 
potassium-magnesium supplementation (13). See Chapter 5 for further discussion.  
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Protocol and Procedures 
A crossover, randomized, double-blinded placebo controlled trial design was 
used (for Methods Flow Chart, see appendix F). Subjects were screened for inclusion 
and exclusion criteria through an online screening questionnaire (see appendix B). 
Those who fit the subject criteria were invited to visit the test location one week prior 
to the start of the trial. At visit 1, participants were asked to record their dietary intake 
for three days in order to assess baseline dietary intake of sodium, potassium, and 
magnesium. This 3-day food record was returned at visit 2. After visit 1, participants 
were stratified by age, gender, BMI, and blood pressure and randomly assigned to one 
of two groups: potassium and magnesium supplement chewy bar or a control chewy bar 
for the first four weeks.  
At baseline (visit 2), participants came in for a second visit and they were 
informed of the treatment protocol and provided with the corresponding chewy bars. 
Baseline measures of height, weight, waist circumference, physical activity and blood 
pressure were collected at visit 2. Four weeks later, participants came in for visit 3. At 
visits 3 and 4, body weight and blood pressure were collected, physical activity 
questionnaire (see appendix G), and a 24-hour food recall were administered and 
participants were provided with the second batch of chewy bars. For the subsequent 
four weeks, the subjects ingested the other corresponding chewy bar (i.e. 
potassium/magnesium or control). Participants were instructed not to change diet or 
exercise habits during the trial. Additionally, participants were instructed to not eat 
within 30 minutes before or after ingesting the chewy bar and not to consume milk 
along with the chewy supplements in order to allow for optimal absorption of minerals. 
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If medication and/or supplement use changed during the trial, participants were asked 
to notify the study investigators.  
The chewy bars were prepared in a commercial kitchen at Arizona State 
University, on the Downtown Phoenix campus. In addition to the minerals used in the 
treatment chewy bars, these bars were prepared using a peanut butter, jelly, and flour 
base of ingredients (see Appendix E). These bars were then weighed and pressed into 
ice cube trays, frozen, portioned and stored in the freezer until given to participants. 
Separate batches (i.e. one for treatment, one for control) of chewy bars were made on 
two occasions, in sufficient quantity to give each participant four weeks of daily 
servings.   
Measurements  
At each visit, body weight was recorded using a calibrated Tanita scale, from 
Tanita Corporation (Arlington Heights, Illinois; model TBF-300A). Blood pressure was 
measured at rest after sitting quietly for 5 minutes using a calibrated blood pressure cuff 
from Omron Healthcare (Bannockburn, Illinois; model HEM-907XL). Three blood 
pressure values recorded at each visit. The first reading was disregarded, and the mean 
values of the 2nd and 3rd blood pressure readings were used as the recorded dependent 
variable. Dependent (paired) sample T-tests were used to compare the mean difference 
of blood pressure changes between the finish of the participants’ 4 weeks adhering to 
the treatment chewy and the finish of the 4 weeks adhering to the control chewy.  In 
order to better control for confounding effects of blood pressure fluctuations, 
participants were asked two questions each visit to identify any abnormal stressors: 1) 
were there any stressful incidences today or last night; 2) did you sleep okay last night. 
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Participants were asked to reschedule appointment if they answered yes to either of 
these two questions.  
Participants completed a three-day 24-hour diet record prior to baseline visit 
(provided at visit 1 [consent visit]) and completed two 24-hour diet recalls, one each at 
both visits 3 and 4. The investigator administered the diet recalls with the participants at 
visits 3 and 4. Dietary intake was recorded in order to measure any differences in 
potassium, magnesium, or sodium intakes between the two experimental groups. 
Dietary data was then analyzed using the online application, The Food Processor. This 
program was used to approximate dietary intake of sodium, potassium, and magnesium.  
Statistical Analysis  
SPSS (Statistical Package for the Social Sciences) v. 22 was used to run 
descriptive and inferential statistical analysis. Results were expressed as the mean ± 
standard deviation (SD). All data were checked for normality. The Shapiro-Wilk test 
was used to check normality due to the small sample size (n = 12). Skewed data (i.e. 
baseline potassium and magnesium intakes; sodium and potassium intakes after 
treatment; and magnesium intake after control) were normalized by being log-
transformed or transformed to square root values. The paired sample T-test was used to 
compare the difference between mean values of the two conditions. For the normally 
distributed data, a Pearson correlation was used to test for correlation. For the non-
normally distributed data that could not be transformed to a normal distribution (i.e. 
systolic blood pressure of the two groups after treatment), the Wilcoxon test was used. 
A p value < 0.05 indicated significant differences between the groups. 
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CHAPTER 4 
RESULTS 
Recruitment 
A total of 34 people completed the online screening questionnaire. Of these 
people, 28 qualified to participate in this study and were solicited. After meeting with 
all 28 respondents for further screening and blood pressure readings, only 12 subjects 
qualified and consented to participate (8 females, 4 males). The 16 respondents who did 
not qualify at initial screening visit were disqualified for having mean blood pressure 
readings outside of the inclusion criteria ranges (i.e. systolic blood pressure: 115-140 
mm Hg; diastolic blood pressure: 70-90 mm Hg). The majority of the disqualified 
respondents were disqualified for having blood pressure below the inclusion criteria. 
Participant characteristics at baseline (visit 2) are displayed in Table 1.  
Descriptive Statistics 
The mean age of subjects was 29.3 years old. Subjects had a mean Body Mass 
Index of 26.2, which is classified as slightly overweight. At baseline visit, mean 
systolic blood pressure was 121.0 ± 12.3 mm Hg and mean diastolic blood pressure was 
75.7 ± 8.8 mm Hg, which was on the lower end of the blood pressure inclusion criteria 
ranges.   
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Table 1: Descriptive Characteristics of all Study Participants at Baseline (n = 12)  
Characteristics  Minimum Maximum Mean 
(± Std. Dev.) 
Age (years) 18 53 29.3 ± 10.9 
Weight (lbs.) 101.8 240.2 174.6 ± 41.7 
Body Mass Index 
(kg/M2) 
19.6 34.8 26.2 ± 4.7 
Height (inches) 65.5 76.0 68.5 ± 3.0 
Activity Level-  
(METS) 
17 99 64.8 ± 29.6 
Systolic BP 
(mm Hg) 
108.5 153.0 121.0 ± 12.3 
Diastolic BP 
(mm Hg) 
62.0 94.0 75.7 ± 8.8 
Energy intake 
(calories/day) 
839.0 2,849.0 1,824.1 ± 593.8 
Sodium intake 
(mg/day) 
1,157.0 4,695.0 2,721.1 ± 1,120.3 
Potassium intake 
(mg/day) 
751.0 3,594.0 1,653.4 ± 834.3 
Magnesium intake 
(mg/day) 
96.0 415.0 179.3 ± 101.2 
 
Treatment Adherence 
All 12 subjects completed the 8-week study, for a 100% retention rate. Ten of 
twelve subjects returned the compliance calendars at the end of the study. Based on 
these 10 calendars, compliance for ingestion of daily treatment was 88.2% and 
compliance for ingestion of daily control was 92.8%. There was no significant 
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difference between the compliance rates of the two groups (p = 0.133). See Table 2. 
During the study there were no complications reported by subjects.   
Systolic, Diastolic, and Average Blood Pressure Values 
 When subjects were asked at each visit if they had encountered any abnormal 
stressful situation in the past 24 hours, the following was noted. At one visit, one 
subject responded that they had taken an exam just prior to the visit, though did not 
consider this abnormal stress. Another subject responded at one visit, that they had been 
taking Sudafed for a cold for the past week. Another subject reported that they had 
taken a yoga class just prior to the study visit, which potentially had an antihypertensive 
effect. Because these subjects did not consider the aforementioned situations 
abnormally stressful, they were not asked to reschedule the visit. The visits proceeded 
according to protocol.  
Contrary to what was anticipated, the treatment group had a slightly higher 
systolic blood pressure (118.3 ± 13.3 mm Hg) than the control group (116.5 ± 17.8 mm 
Hg); however, diastolic blood pressure was slightly lower in the treatment group (71.7 
± 12.4 mm Hg) compared to the control group (73.0 ± 10.0 mm Hg). However, there 
were no statistical differences found in systolic or diastolic blood pressures between the 
treatment and control chewies (p = 0.645 and p = 0.464, respectively). Additionally, 
there was no significant difference in average blood pressure blood pressure values 
between the treatment and control chewies (p = 0.939). There was however a 
significant difference (p = .030) for body weights between the treatment and control 
chewies. See Table 2.  
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Table 2. Blood Pressure, Weights, and Physical Activity Levels 
  Treatment  
(Mean ± SD) 
Control  
(Mean ± SD) 
Significance 
(2-tailed) 
Systolic BP 
(mm Hg)  
118.3 ± 13.3 116.5 ± 17.8 0.964* 
Diastolic BP 
(mm Hg) 
71.7 ± 12.4 73.0 ± 10.0 0.464 
Average BP 
(mm Hg) 
95.0 ± 10.8 94.8 ± 12.7 0.939 
Physical activity 
(METS)  
67.0 ± 37.2 66.7 ± 44.3 0.953 
Weight (kilograms) 81.6 ± 5.6 81.0 ± 5.6 0.030** 
Caloric intake (24-
hour recall) 
1,836.5 ± 452.4  1,802.2 ± 827.0 0.912 
Body Mass Index 
(kg/ m2) 
26.34 ± 4.50 26.31 ± 4.44 0.783 
Compliance 
(percentage of trial 
days, chewy ingested) 
88.2 ± 15.5 92.8 ± 5.8 0.133 
All values represent mean ±Standard Deviation (SD)  
*Non-parametric data, Wilcoxon test was used  
**Significant difference in mean blood pressure value between the treatment and control chewies 
were determined at the .05 level.  
 
Body Weight and Body Mass Index 
Subjects had a mean Body Mass Index (BMI) of 26.2 ± 4.7, at baseline. Body 
weight was significantly higher following the treatment period, compared to the control 
period (p = 0.030) (179.5 ± 12.3 lbs. and 178.1 ± 12.3 lbs., respectively). However, 
there was not a significant difference of BMI between the treatment and control 
chewies (p = 0.783).  
Physical Activity Questionnaire 
At visits 2, 3 and 4 (weeks 0, 4 and 8, respectively) the participants completed a 
physical activity questionnaire (see Appendix G). The mean value of approximated 
weekly METS for the treatment group was 67.0 ± 10.7 and 66.7 ± 12.8 for the controls. 
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There was no significant difference of physical activity between the treatment and 
control chewies (p = 0.953).   
Potassium, Magnesium, and Sodium Intakes  
The mean values of sodium, potassium, and magnesium intakes during the 
treatment period were 3,746 ± 714 mg/day, 2,403.3 ± 1,030.4 mg/day and 280.1 ± 
104.8 mg/day, respectively. During the control period nutrient intakes were 4,484 ± 800 
mg/day, 1,681 ± 310 mg/day and 261± 73 mg/day, respectively. Sodium, potassium, 
and magnesium intake levels were log transformed to normalize the data for both the 
treatment period (Shapiro-Wilk test of normality p = 0.700, 0.295 and 0.401 
respectively) and the control period (Shapiro-Wilk test of normality p = 0.785, p = 
0.358 and 0.390). There were no significant differences for the dietary intakes of 
sodium, potassium and magnesium between the two groups (p = 0.552, p = 0.068 and p 
= 0.826, respectively) See Table 3.  
Table 3. Dietary intakes of sodium, potassium, and magnesium 
 Treatment Control Significance 
(2-tailed) 
Sodium 
(mg/day) 
3,745.8 ± 2.474.9 4,484.4 ± 2,772.6 0.552 
Potassium 
(mg/day) 
2,403.3 ± 1,030.4 1,680.7 ± 1,074.1 0.068 
Magnesium 
(mg/day) 
280.1 ± 104.8 261.4 ± 254.0 0.826 
All values are represented in mg/day as Mean ±SD.  
*Significant difference in mean blood pressure value between the treatment and the control periods were 
determined at the .05 level using log transformed values. 
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CHAPTER 5 
DISCUSSION 
Although great progress has been made in the past two decades for awareness, 
treatment and control of hypertension, the continual rise in prevalence of hypertension 
demands alternative approaches to combat this arterial disease (2). Despite the 
recognized antihypertensive effects of potassium and magnesium in clinical settings for 
nearly a century, actualizing the potential utility of these minerals to manage 
prehypertension has been challenging to achieve (19, 20). Barriers that impede updating 
guidelines to promote increasing intake of potassium and magnesium include 
inconsistency of research findings, heterogeneous study designs and sample 
populations, and short duration of intervention trials (65-67).  
 Furthermore, there are various effects induced from a variety of types (i.e. 
elemental compounds) of potassium and magnesium supplements. For instance, Keith 
and colleagues compared the natriuretic effects of different potassium salts: potassium 
citrate, chloride, bicarbonate, acetate, and potassium nitrate (68). All potassium salts 
compared produced significant natriuretic effects, however potassium nitrate had the 
most significant natriuretic effect compared to the other salts. Because of such 
heterogeneity in study designs, there is not a standard recommendation for 
supplementing these nutrients for the purpose of lowering blood pressure.  
Rather than focus on treatment once essential hypertension develops, this study 
examined the utility of potassium and magnesium supplementation for pre-hypertensive 
individuals. This study therefore suggests an alterative and non-didactic approach for 
consumers to manage slightly elevated blood pressure before considering medications. 
  45 
This relationship was researched to ascertain whether daily supplementation of 
potassium and magnesium would decrease blood pressure in individuals with mildly 
elevated blood pressure.  
Blood Pressure 
After four weeks of supplement intake, there were no significant differences in 
systolic (SBP) or diastolic blood pressures (DBP) (p = 0.964 and 0.464, respectively) 
between those in the treatment group (mean = 118.3 mm Hg SBP, 71.7 mm Hg DBP) 
and those in the control group (mean = 116.5 SBP, 73.0 mm Hg DBP). According to 
these results it appears that the treatment (217.2 mg/day potassium and 70.8 mg/day 
magnesium) did not have any significant antihypertensive effects.   
It is possible that potassium and magnesium do have antihypertensive effects in 
a population with mild-moderately elevated blood pressure, however the dosage in the 
present study was not adequate for this effect. The dosage of potassium for those in the 
treatment group was only 5% (daily) of the Adequate Intake (AI) value for potassium, 
while the daily dose of magnesium was only 18% for males, 23% for females of the 
Recommended Dietary Allowance (RDA). The study that was used to base the present 
study’s dosage values on, conducted by Wu et al, found a reduction of 7.83 ± 1.87 mm 
Hg SBP (p < 0.01) and 3.67 ± 1.03 mm Hg DBP (p < 0.05) on four weeks of 
potassium-magnesium supplementation (13). These significant results were from a 
population of 35 subjects (10 males, 25 females) with a mean age of 58 ± 7 years, 
living in the Shaanxi district, China. Unlike the population of the present study, Wu and 
colleagues included subjects who were concomitantly taking blood pressure 
medications. Furthermore, Wu and colleagues found significant results with this 
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particular dosage of potassium-magnesium supplementation in a hypertensive 
population, with mean baseline blood pressure of 142.3 mm Hg SBP, 82.5 mm Hg DBP 
(13). This is important to note considering that baseline blood pressure of the present 
study was approximately 15% and 8% lower for systolic and diastolic blood pressure, 
respectively, compared to Wu and colleagues baseline characteristics. Other research 
suggests that the antihypertensive effects of potassium are largely influenced by the 
baseline blood pressure (14). That is, the greater the baseline blood pressure values, the 
greater the antihypertensive effect of potassium and magnesium.  
Mullen and colleagues conducted a randomized, double blind placebo 
controlled study, comparing the antihypertensive effect of different potassium salts (i.e. 
potassium chloride and potassium citrate) with a population of 24 normotensive adult 
males (69). There were no significant changes of blood pressure after supplementation 
of potassium chloride or potassium citrate among these normotensive subjects. The 
daily dosage of potassium chloride/citrate was approximately 2,940 mg/day (75 
mmol/day). Average intakes of potassium in modern societies are approximately 2,745-
3,136 mg/day (70-80 mmol/day), therefore Mullen’s study approximately doubled daily 
potassium intake in these normotensive males and there was no significant changes to 
blood pressure (33). Despite showing promising results in a normotensive population, 
the efficacious value used in Mullen and colleagues’ study exceeded 10 times the 
amount used in the present study.  
On the contrast, Braschi and colleagues tested blood pressure effects of different 
potassium salts (i.e. potassium chloride and potassium citrate) on normotensive 
individuals, with less than 50% of the amount of potassium used in Mullen and 
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colleagues’ study (69) and found hypotensive results from supplementation of both 
potassium citrate and potassium chloride (14). In this 6-week, randomized double blind 
placebo controlled trial, subjects were given approximately 1,180 mg/day (30 
mmol/day) of potassium citrate, potassium chloride, or a placebo. The findings indicate 
that supplementation of both potassium salts were effective at lowering mean arterial 
blood pressure in normotensive individuals. Compared with the control group, six 
weeks of supplementation of potassium chloride, potassium citrate resulted in a 
decrease of -4.70 mm Hg and -5.22 mm Hg, respectively. There was not a significant 
difference between the antihypertensive effects of the two salts.  
However, the more interesting finding is that there was a significant correlation  
(p = 0.007) found between SBP and the change in SBP from baseline to end of the trial. 
This illustrated that the reduction in SBP values after the 6-week trial was greater in 
those with higher SBP values. Concluding Braschi and colleagues’ study, the 
antihypertensive effect of potassium supplementation was independent of the type of 
potassium salts, and was greater in those with elevated SBP at baseline.  
Despite Braschi and colleagues’ study administering a higher potassium dosage 
than the present study, the finding of the relationship between baseline SBP and change 
in SBP after potassium supplementation potentially indicates why there was no 
significant changes in blood pressure found with the given relatively low dosages of the 
current study (i.e. only 5% daily Adequate Intake for potassium and approximately 
20% of Recommended Dietary Allowance for magnesium). Considering the blood 
pressure range of this current study (inclusion criteria: SBP- >115 mm Hg and <139 
mm Hg; DBP- >70 mm Hg and <90 mm Hg) and the relatively low dosages of 
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potassium and magnesium supplementation, there were no significant changes in blood 
pressure of individuals with slightly elevated blood pressure. Although, the aim was to 
recruit a population with mild-moderately elevated blood pressure, the population that 
was recruited had a baseline blood pressure only slightly above optimal (121.0/75.7 
mm Hg).  
Compared to other efficacious studies of both potassium and magnesium 
supplementation individually, the dosage values used in the present study were the 
lowest. For instance, other controlled trials demonstrating significant hypotensive 
effects on potassium supplementation varied from dosages of 1,170 mg/day and even 
exceeding ten times the amount used in the present study, with dosage values of 3,000 
and even 4,680 mg/day, with no reported adverse health outcomes (14-16). Similarly, 
hypotensive dosages of magnesium used in other controlled trials range from 368 
mg/day to 600 mg/day (17, 18). 
Body Weight 
After four weeks of following supplement protocol, body weight after the 
treatment period was significantly higher than body weight after the control period (p = 
0.030) (179.5 ± 12.3 and 178.1 ± 12.3 pounds, respectively). With less than one 
kilogram, the difference in body weight may be related to fluid status, which is not 
detected on the Tanita scale that was used to measure body weight and body 
composition. Fluid status naturally fluctuates in humans, throughout the day. For 
instance, if one subject is more hydrated than another subject with the same body 
composition, the individual that is more hydrated will be read as having a leaner body 
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composition, due to the ability of water to hasten the electrical current that is used in 
bioelectrical impedance. 
Physical Activity 
There was no significant difference between the physical activity levels of the 
treatment and control periods (p = 0.953). There were no differences in physical 
activity levels anticipated between the two groups because all participants were asked 
to maintain physical activity patterns for the duration of the 8-week study.  
Sodium, Potassium, and Magnesium Intakes 
The mean daily intake of sodium, for all participants after the four weeks of 
ingesting the chewy bars (including treatment and placebo) was 4,115 mg/day. These 
high sodium intakes are greater than some estimates of the average daily intake in the 
United States, which approximate daily sodium intakes at 3,500 mg/day (7). A 
Tolerable Upper Limit (UL) has been established for sodium and recommends limiting 
sodium intake to less than 2,300 mg/day. The UL for sodium was established based on 
the finding that excessive sodium promotes hypertension and is problematic for 
individuals with kidney disease (43). There was no significant difference in the 
approximated dietary intake of sodium between the two groups (p = 0.552).  
The high sodium intake of the subjects in the present study, in conjunction with 
the lack of significant blood pressure changes between the treatment and control is an 
interesting finding given that there is a correlation between sodium intake and the 
natriuretic effect of potassium supplementation (54). One study investigated the effect 
that the same dosage of potassium load (3,920 mg/day) had on varying sodium intake 
levels. Compared to the low and moderate levels of sodium intake, the subjects with the 
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highest level of sodium intake demonstrated the highest level of sodium excretion after 
potassium loading (54). However, the dosage of potassium in the present study was 
considerably lower; therefore the dosage of potassium was not likely an adequate 
quantity to cause any significant changes in blood pressure. 
The average dietary intake of potassium, for all participants after the four weeks 
of ingesting the chewy bars was 2,042 mg/day. This average intake is less than half of 
the Adequate Intake (AI) for potassium, which is 4,700 mg/day for adults. Further, the 
dosage of potassium given in the current study was less than 5% of the AI value. 
Although there was not a significant difference of potassium intakes between the 
treatment and control (p = 0.068), there was a 43% increase in potassium intake 
approximated in the treatment group. However, these dietary data have considerable 
limitations that need to be mentioned. The dietary analysis database used (The Food 
Processor), like other dietary databases, does not provide all the possible food products 
available in order to reliably select the most valid food products and measure accurate 
dietary profile information.  
The average magnesium intake for all participants after the four weeks of 
ingesting the chewy bars was approximately 271 mg/day. These intake values equate to 
approximately 50%-75% of the Recommended Dietary Allowance (RDA) for 
magnesium. Another important limitation is that these dietary data were measured from 
a food record and from two separate 24-hour food recalls. These limited measures of 
dietary intake are only brief appraisals of subjects’ diets, and is not necessarily 
representative of subjects’ average dietary intakes.   
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CHAPTER 6 
CONCLUSION 
Data from this research suggest that daily supplementation of potassium and 
magnesium (217.2 mg/day and 70.8 mg/day, respectively) does not significantly 
decrease blood pressure in individuals with mildly-moderately elevated blood pressure. 
Increased blood pressure is strongly linked with risk of cardiovascular disease and 
stroke (22) as well as other chronic conditions including cerebrovascular disease, 
ischemic heart disease, and renal failure (23).  
These results may not be completely representative of the population at large 
because a small sample size (n = 12) was used, only college students and university 
staff were included in the sample, and baseline blood pressures were only mildly 
elevated (baseline mean blood pressure = 121/75 mm Hg). Research demonstrates that 
the antihypertensive effects of potassium and magnesium are potentiated with greater 
baseline blood pressure values (14). Furthermore, the dosage levels of potassium and 
magnesium (<5% Adequate Intake and approximately 20% Recommended Dietary 
Allowance, respectively) in the current study were not substantial with regard to the 
aforementioned Dietary Reference Intakes of each of the two essential minerals and 
baseline blood pressures.  
Additional research is needed to determine if higher dosages of potassium and 
magnesium will have a significant impact on individuals with mild-moderately elevated 
blood pressure. Future studies should use a larger sample size; explore the 
antihypertensive effects of larger doses of potassium and magnesium, and the effect of 
these minerals on variant levels of sodium intake.   
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1. Please provide your email address: 
2. Please select your gender 
3. What is your age? 
4. Please enter your height and weight 
5. Do you have (or think you have) food allergies? 
6. Do you take any dietary supplements daily? (e.g. vitamin, mineral, and/or herb) 
a. If yes (please specify) 
7. Has a doctor ever told you that you have high blood pressure? 
8. Do you know your blood pressure 
a. If yes, what was the last reading you remember? 
9. Do you have any active disease state that is currently requiring medication?  
10. If female, are you pregnant, lactating, or do you anticipate becoming pregnant? 
11. If you smoke, please select how many cigarettes you smoke per day 
12. How many times per week do you participate in vigorous, highly intense 
exercise? 
13. Are you following a special diet (such as vegetarian or gluten-free)? 
a. If yes, please specify 
14.  Will you be able to maintain your current diet and physical activity patterns for a 
consecutive 8 weeks?  
15. Are you willing and able to travel to either the ASU Campus in Tempe or the 
ASU Downtown Campus to meet with research investigators on five separate 
occasions? (<20 minutes/visit) 
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Adults Needed for ASU Supplement Trial 
 
Title of research study: Hypotensive Effects of Potassium and Magnesium 
Why am I being invited to take part in a research study? 
 
ASU School of Nutrition and Health Promotion professor Dr. Carol Johnston and graduate 
student Jason Pawloski invite you to take part in a research study. ASU Nutrition Program is 
inviting healthy adults (18 years of age) who have mildly elevated blood pressure to be part of a 
research trial. 
Why is this research being done? The	  purpose	  of	  this	  research	  is	  to	  determine	  if	  a	  mineral	  preparation	  (potassium	  and	  magnesium)	  significantly	  decreases	  blood	  pressure	  for	  individuals	  with	  mildly	  elevated	  blood	  pressure.	  Additionally,	  this	  research	  aims	  to	  contribute	  to	  the	  building	  base	  of	  evidence	  suggesting	  that	  potassium	  and	  magnesium	  supplementation	  can	  reduce	  or	  replace	  blood	  pressure	  medications.	  	  Today,	  the	  primary	  treatment	  methods	  for	  hypertension	  (“high	  blood	  pressure”)	  in	  the	  U.S.	  are	  prescribed	  medications.	  Although	  there	  is	  already	  a	  proven	  effective,	  nationally	  recommended	  dietary	  remedy	  (the	  DASH	  Diet)	  for	  lowering	  hypertension,	  knowledge	  of	  and	  adherence	  to	  this	  diet	  are	  not	  substantial	  enough	  to	  decrease	  the	  overall	  prevalence	  of	  hypertension.	  	  Potential	  benefits	  resulting	  from	  this	  research	  include	  new	  evidence	  supporting	  the	  effectiveness	  and	  feasibility	  of	  simply	  taking	  a	  mineral	  supplement	  (a	  ‘functional	  food’)	  to	  help	  decrease	  hypertension	  rather	  than	  relying	  on	  medications.	  	  	  
How long will the research last? The	  research	  trial	  will	  last	  8	  weeks	  and	  will	  entail	  a	  total	  of	  4	  visits	  with	  investigators.	  Each	  visit	  will	  last	  approximately	  15-­‐20	  minutes.	  	  
What happens if I say yes, I want to be in this research? 
It is up to you to decide whether or not to participate. If you decide to participate, 
the 4 office visits will be conducted in the following sequence:  
Screening visit, start of research trial (week 0), week 4, and week 8.   
At each visit, blood pressure and body weight will be recorded. The visits will be 
conducted in the ABC Building (on 5th street and Van Buren) on the ASU 
Downtown Phoenix Campus and you will be meeting with investigator Jason 
Pawloski.  
 
 
What happens if I say yes, but I change my mind later? You	  can	  leave	  the	  research	  at	  any	  time	  it	  will	  not	  be	  held	  against	  you.	  If	  you	  decide	  to	  leave	  the	  research,	  contact	  the	  investigator	  so	  the	  investigator	  can	  withdraw	  you	  from	  the	  study.	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Who can I talk to? 
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the 
research team at: Dr. Carol Johnston (602) 827-2265, carol.johnston@asu.edu; or Jason Pawloski 
(623) 293-2518, jrpaulso@asu.edu. 
 This	  research	  has	  been	  reviewed	  and	  approved	  by	  the	  Bioscience	  IRB	  (“Institutional	  Review	  Board”).	  You	  may	  talk	  to	  them	  at	  (480)	  965-­‐6788	  or	  research.integrity@asu.edu	  if:	  
• Your	  questions,	  concerns,	  or	  complaints	  are	  not	  being	  answered	  by	  the	  research	  team.	  
• You	  cannot	  reach	  the	  research	  team.	  
• You	  want	  to	  talk	  to	  someone	  besides	  the	  research	  team.	  
• You	  have	  questions	  about	  your	  rights	  as	  a	  research	  participant.	  
• You	  want	  to	  get	  information	  or	  provide	  input	  about	  this	  research.	  	  	  	  	  	  	  	  	  	  
	  
	  
Your signature documents your permission to take part in this research. 
   
Signature of participant  Date 
  
Printed name of participant 
   
Signature of person obtaining consent 
 
 
 Date 
                   Printed name of person obtaining consent 
 
 	  
Printed name of person witnessing consent process  
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APPROVAL: MODIFICATION 
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Carol Johnston  
SNHP – Nutrition 
602/827-2265  
CAROL.JOHNSTON@asu.edu 
 
Dear Carol Johnston: On 2/5/2014 the ASU IRB reviewed the following protocol: 
 
Type of Review: Modification 
Title: The hypotensive effect of hawthorn berry extract in healthy adults with mild 
hypertension 
Investigator: Carol Johnston 
IRB ID: STUDY00000015 
Funding: None 
Grant Title: None 
Grant ID: None 
Documents Reviewed: 
• Consent, Category: Consent Form;  
• consent (hawthorn berry), Category: Consent Form;  
• Consent (minerals), Category: Consent Form;  
• updated hawthorn berry consent, Category: Consent Form;  
• CONSENT FORM4minerals.pdf, Category: Consent Form;  
• Protocol, Category: IRB Protocol; • Mood measure, Category: Measures (Survey 
questions/Interview questions /interview guides/focus group questions);  
• Sleep measure, Category: Measures (Survey questions/Interview questions /interview 
guides/focus group questions);  
• Calendar, Category: Participant materials (specific directions for them);  
• Verbal script/online ad, Category: Recruitment Materials;  
• Verbal script/online ad (minerals), Category: Recruitment Materials: 
• Online survey, Category: Recruitment materials/advertisements /verbal scripts/phone 
scripts; • Health history questionnaire, Category: Screening forms;  
• Checksheet, Category: Screening forms;  
• Herbalist diploma, Category: Vitaes/resumes of study team; 
 
The IRB approved the modification. 
When consent is appropriate, you must use final, watermarked versions available under 
the “Documents” tab in ERA-IRB. 
In conducting this protocol you are required to follow the requirements listed in the 
INVESTIGATOR MANUAL (HRP-103). 
Sincerely, 
 
IRB Administrator 
Continuing Review – 2014 (00000015) Hypotensive effect of Hawthorne Berry Extract 
This protocol covers two blood pressure intervention trials involving natural 
supplements:  Hawthorne berry extract and potassium/magnesium.  25 participants 
completed the Hawthorne berry extract trial and 12 participants completed the 
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potassium/magnesium trial.  We will leave the protocol open for future enrollment 
(although this is unlikely).  Data are currently being entered into spreadsheets for 
analyses.  Preliminary data from the potassium/magnesium trial indicate a non-significant 
reduction in blood pressure due to the active treatment.   
There were no complications reported by participants.  In the next year, an honors thesis 
and an MS thesis should be completed based on this research.   
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Potassium/Magnesium calculations (treatment only): 
 
Treatment dosage: 217.2 mg/day potassium and 70.8 mg/day magnesium  
Total participants expected- 30-40 (~15-20/group) 
 
Potassium needed: 
 
217.2mg/day X 15 (subjects) X 56 (i.e. 8 weeks) = 182,448mg/1000 = 182.5 grams 
182.5 g/ 28 (g/oz.) = 6.52 oz. 
 
Test- trial batch (per serving calc.)-  
 
365mg (supp. serving)/ 217.2mg K = 1.68;  
So, 0.7 (supp. dosage)/ 1.68 = 0.417g powder needed/dosage 
 
K+ Supp. powder needed/batch: 
 
15 (subjects) x 56 days x 0.417g = 350.28 grams (for 8 week batch, 15 subjects) 
23.35g/subject batch 
 
 
 
Magnesium needed: 
 
70.8 mg/day X 15 (subjects) X 56 (8 weeks) = 59,472mg/1000 = 59.5 grams 
59.5 g/ 28 = 2.125 oz./16 = 0.13 pounds of Magnesium/treatment batch  
 
 
Test- trial batch (per serving calc.)-  
 
300mg Mg (supp. serving)/ 70.8mg Mg = 4.24; 
So, 4,000 mg (supp. dosage)/ 4.24 = 0.943 grams powder needed/dosage 
 
 
Mg+ supp. powder needed/batch-  
 
15 (subjects) x 56 days x 0.943g = 792.12 grams (8 wk. batch, 15 subjects) 
52.81g/subject 
 
 
 
 
 
 73 
Non-mineral Ingredients calculations (treatment and placebo): 
 
Peanut Butter needed  
 
10g/serving x 30 subjects x 56 days (8 weeks) = 16,800g  
 
16,800/28 = 600 oz. 
 
600oz./ 16 = 37.5lbs. Peanut Butter  
 
1.25lbs. /subject batch 
567g 
 
 
Jelly needed  
 
5g/serving x 30 subjects x 56 days = 8,400g 
 
8,400g/28= 300 oz.  
 
300oz./16= 18.75 lbs. Jelly  
 
0.625lbs. /subject batch 
283.5g 
 
AP Flour 
 
2g/serving x 30 x 56 = 3,360g 
 
3,360g/28= 120oz.  
 
120oz./16= 7.5 lbs. AP flour 
 
0.25lbs. /subject batch 
113.4g 
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List	  Serve	   •  Email	  invites	  •  Medical	  History	  Questionnaire	  
Visit	  1:	  Screening	  
•  Consented	  subjects	  •  Measured	  anthropometrics	  and	  baseline	  blood	  pressure	  
Visit	  2:	  (Week	  0/Baseline)	  
•  Measured	  anthropometrics	  and	  blood	  pressure	  •  Provide	  4	  weeks	  of	  portioned	  chewy	  bars	  
Visit	  3:	  (Week	  4)	  
•  Measured	  anthropometrics	  and	  blood	  pressure	  •  Provide	  4	  weeks	  of	  portioned	  chewy	  bars	  •  Provided	  $15	  Target	  gift	  card	  
Visit	  4:	  (Week	  8)	  
•  Measured	  anthropometrics	  and	  blood	  pressure	  •  Provided	  $25	  Target	  gift	  card	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ID# ___________________   Date of baseline visit (visit #2) ____________________ 
 
 
Please circle the number of times you did the following kinds of exercises for more 
than 15 minutes last week.  
 
• Mild	  exercise	  (minimal	  effort):	  
Easy walking, golf, gardening, bowling, yoga, fishing, horseshoes, archery, etc.  
 
Times per week: 0   1   2   3   4   5   6   7   8   9   10   11   12   13   14+ 
 
• Moderate	  exercise	  (not	  exhausting):	  
Fast walking, easy bicycling, tennis, easy swimming, badminton, dancing, volleyball, 
baseball, etc.  
 
Times per week:   0   1   2   3   4   5   6   7   8   9   10   11   12   13   14+ 
 
• Strenuous	  exercise	  activities	  (heart	  beats	  rapidly):	  
Running, jogging, hockey, football, soccer, squash, basketball, cross country skiing, 
judo, roller skating, vigorous swimming, vigorous long distance bicycling, etc.  
 
Times per week:   0   1   2   3   4   5   6   7   8   9   10   11   12   13   14+ 
 
 
 
 
 
 
 
 
 
 
 78 
APPENDIX H 
 
SAMPLE SIZE CALCULATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 1 2 3 4 
Author Sarkkinen et al Wu et al Patki et al Naismith DJ, 
Braschi A. 
Year 2011 2006 1990 2003 
SBP Decrease 
(mm Hg) 
7.5 ± 10.1 7.83 ± 11.1 11.2 ± 11.2 8.4 ± 22.1 
 
DBP Decrease 
(mm Hg) 
2.7 ± 4.5 3.67 ± 1.03 12.2 ± 5.0 6.46 ± 
n per group 
(number of 
subjects in study) 
22 35 37 30 
Calculated n per 
group 
30  33 17 110 
Age Range (years) 25 - 75 41 - 70 49.9 ± 7.6 22-65 
Subject state BMI: 23-40; 
SBP: 130-159; 
DBP: 85-99 
EH=  
SBP ≥140 
DBP ≥90 
EH= Mean BP- 
SBP: 155 
DBP: 100.4 
“Apparently 
healthy” 
 
Study design/ 
duration 
RCT; 8 weeks RCT; 4 weeks Crossover; 8 
weeks 
RCT; 6 weeks 
 
